Eugene Park - MEI Pharma VP Marketing

MEIP Stock  USD 2.55  0.15  5.56%   

Insider

Eugene Park is VP Marketing of MEI Pharma
Address 9920 Pacific Heights Blvd., San Diego, CA, United States, 92121
Phone(858) 369-7100
Webhttps://meipharma.com

MEI Pharma Management Efficiency

The company has return on total asset (ROA) of 0.2004 % which means that it generated a profit of $0.2004 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.6168 %, meaning that it created $0.6168 on every $100 dollars invested by stockholders. MEI Pharma's management efficiency ratios could be used to measure how well MEI Pharma manages its routine affairs as well as how well it operates its assets and liabilities. As of 12/16/2024, Return On Tangible Assets is likely to grow to 0.45. Also, Return On Capital Employed is likely to grow to 0.46. At this time, MEI Pharma's Liabilities And Stockholders Equity is relatively stable compared to the past year. As of 12/16/2024, Non Current Liabilities Other is likely to grow to about 26.8 M, while Total Current Liabilities is likely to drop slightly above 8.3 M.
MEI Pharma currently holds 8.36 M in liabilities with Debt to Equity (D/E) ratio of 0.18, which may suggest the company is not taking enough advantage from borrowing. MEI Pharma has a current ratio of 6.7, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about MEI Pharma's use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

INSIDER Age

MHROD SHRMSCPAssembly Biosciences
N/A
Ian CritchleySpero Therapeutics
N/A
Marine PopoffHookipa Pharma
N/A
Rabia MDOcular Therapeutix
55
Adam ZlotnickAssembly Biosciences
N/A
Uri MDAssembly Biosciences
52
Prof MDHookipa Pharma
80
James BradySpero Therapeutics
N/A
Qiyong LiuTranscode Therapeutics
60
Mark VignolaTerns Pharmaceuticals
46
Jamie MooreCytomX Therapeutics
N/A
John MDVincerx Pharma
N/A
Julia WilsonAchilles Therapeutics PLC
N/A
Alexandra MDAvenue Therapeutics
57
Chester IIIRevelation Biosciences
44
David JinAvenue Therapeutics
34
Susannah WalpoleSpero Therapeutics
N/A
Reinhard KanderaHookipa Pharma
55
Weidong ZhongTerns Pharmaceuticals
58
Charles IIDay One Biopharmaceuticals
47
Sumita JDInstil Bio
50
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California. Mei Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 102 people. MEI Pharma (MEIP) is traded on NASDAQ Exchange in USA. It is located in 9920 Pacific Heights Blvd., San Diego, CA, United States, 92121 and employs 28 people. MEI Pharma is listed under Biotechnology category by Fama And French industry classification.

Management Performance

MEI Pharma Leadership Team

Elected by the shareholders, the MEI Pharma's board of directors comprises two types of representatives: MEI Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of MEI. The board's role is to monitor MEI Pharma's management team and ensure that shareholders' interests are well served. MEI Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, MEI Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
BA Esq, COO Counsel
Anne Frese, Chief Officer
Eugene Park, VP Marketing
Virginia Sankey, VP Fin
JD Esq, Chief Officer
Eric Deng, VP Operations
Richard Ghalie, Chief Officer
MBA MD, Chief Officer
LLM JD, Senior Affairs
Robert Mass, Chief Medical Officer
BA CPA, CFO Sec
Justin File, CFO Secretary
Nicole Iida, Vice Affairs
Daniel Gold, CEO and President and Director
Yomara GomezNaiden, Senior Quality

MEI Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is MEI Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with MEI Pharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if MEI Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in MEI Pharma will appreciate offsetting losses from the drop in the long position's value.

Moving against MEI Stock

  0.55FLGC Flora Growth CorpPairCorr
  0.37DYAI Dyadic InternationalPairCorr
  0.35DNA Ginkgo Bioworks HoldingsPairCorr
  0.32ESPR Esperion TherapeuticsPairCorr
  0.32IMAB I MabPairCorr
The ability to find closely correlated positions to MEI Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace MEI Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back MEI Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling MEI Pharma to buy it.
The correlation of MEI Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as MEI Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if MEI Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for MEI Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for MEI Stock Analysis

When running MEI Pharma's price analysis, check to measure MEI Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MEI Pharma is operating at the current time. Most of MEI Pharma's value examination focuses on studying past and present price action to predict the probability of MEI Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MEI Pharma's price. Additionally, you may evaluate how the addition of MEI Pharma to your portfolios can decrease your overall portfolio volatility.